^
Association details:
| Biomarker: | KMT2C mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of KMT2C mutations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
Published date:
05/19/2021
Excerpt:
A multivariable analysis across the pan-cancer cohort using Cox proportional-hazards regression demonstrated that KMT2C mutation was significantly associated with better OS (hazard ratio, 0.69; 95%CI, 0.52-0.90; P = 0.006), and association remained significant with bladder (P = 0.039), colorectal (P = 0.024), melanoma (P < 0.001) and renal (P < 0.001)...
DOI:
10.1200/JCO.2021.39.15_suppl.2600
